|
|
|
51-200 employees
View all
|
|
Biotechnology
|
|
200 CambridgePark Drive, Cambridge, Massachusetts 02140, US
|
|
Cogent Biosciences is a biotechnology company developing real solutions to treat genetically driven diseases. With a focus on rational drug discovery and development, we are leveraging validated biology to advance precision therapies designed to address the true underlying drivers of disease and provide real hope for patients. Cogent’s lead therapeutic candidate, PLX9486 (expected to be named CGT9486 in the future), is a precision kinase inhibitor designed to selectively and potently inhibit the KIT D816V mutation. This mutation is responsible for driving a rare and serious condition called Systemic Mastocytosis which can severely impact many different tissues and organs in the body. We are also studying PLX9486 to treat advanced gastrointestinal stromal tumors (GIST), which have a strong dependence on oncogenic KIT signaling.
|
Cogent Biosciences Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
75.00%
|
The widely used Cogent Biosciences email format is {f}{last} (e.g. [email protected]) with 75.00% adoption across the company.
To contact Cogent Biosciences customer service number in your country click here to find.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.